Prostate cancer.

Guideline ID: 1793 Published: 2025 Mar

European Association of Urology (EAU) | European Association of Nuclear Medicine (EANM) | European Society for Radiotherapy and Oncology (ESTRO) | European Society of Urogenital Radiology (ESUR) | International Society of Urological Pathology (ISUP) | International Society of Geriatric Oncology (SIOG)

Cornford P, Tilki D, van den Bergh RCN, et al. Prostate cancer. Arnhem (Netherlands): European Association of Urology (EAU); 2025 Mar. 251 p. [1594 references]

View Original Guideline

Overview

Guideline Objective

To assist medical professionals in the evidence-based management of prostate cancer (PCa)

Patient Population

Men with suspected or confirmed PCa

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Epidemiology and aetiology, including risk factors
- Classification and staging systems
- Diagnostic evaluation, including screening and early detection, digital rectal examination, prostate-specific antigen, biomarkers, imaging, biopsy, staging according to risk, and evaluation of health status and life expectancy
- Treatment modalities, including active surveillance strategy, radical prostatectomy, radiotherapy, hormonal therapy, and investigational therapies
- Treatment by disease stages (e.g., low-, intermediate-, and high-risk), and options for metastatic disease and castrate-resistant disease
- Management of prostate-specific antigen (PSA)-only recurrence
- Quality of life and follow-up considerations

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Search Strategy.

- European Association of Urology Guidelines Office Development Handbook; 2025 Jul.

Implementation Tools

- Pocket Guidelines; 2025 Mar.
- E-course: EAU Guidelines on Prostate Cancer; 2015 Mar 1.
- Cheat Sheet: Epidemiology, Aetiology, Classification And Diagnosis I; 2022.
- Cheat Sheet: Diagnostic Evaluation II; 2022.
- Cheat Sheet: Treatment by Disease Stages; 2025.
- Cheat Sheet: Treatment I; 2023.
- Cheat Sheet: Treatment II; 2024.
- Podcast: Prof. Nicolas Mottet about the Changes in the 2022 Guidelines for Prostate Cancer:
    - Part 1; 2022 Apr 3.
    - Part 2; 2022 Apr 14.

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using

these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2025 ECRI